Revanesse® is recognised for its favourable safety profile, with comparative analyses of adverse-event reports in the US Food and Drug Administration’s (FDA) MAUDE database suggesting a low proportion of reported complications relative to certain competing hyaluronic acid dermal fillers. This post-market surveillance data, alongside clinical research, gives medical aesthetic practitioners valuable insight into Revanesse’s safety and performance.
In a comparative clinical study, Revanesse fillers showed lower reported rates of injection-site swelling (47.2% versus 71.2%) and pain (38% versus 66.3%) than a comparator. Together, these findings support Revanesse’s safety profile and provide practitioners with additional confidence when evaluating the brand for their injectable portfolio.




